GlassScriptPhysician profile
James F Anoia
NPI 1588647572
$1,905.52
in general payments reported to CMS, 2019-2025
29 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.89 · 2020: $115 · 2021: $130 · 2022: $214 · 2023: $451 · 2024: $429 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $272.38 | 2020-2025 | |
| Novo Nordisk INC | $254.20 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $208.35 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $114.34 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $113.56 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $97.36 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Amgen INC. | $90.67 | 2021-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.11 | 2023-2025 | Xifaxan |
| Abbvie INC. | $65.72 | 2023-2024 | Ubrelvy, Qulipta, Vraylar |
| Vital Connect, INC | $51.21 | 2023 | Vitalpatch Rtm |
| Bayer Healthcare Pharmaceuticals INC. | $50.44 | 2022-2023 | |
| Esperion Therapeutics, INC. | $50.38 | 2021-2025 | Nexletol |
| Dexcom, INC. | $48.63 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $47.91 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $44.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.79 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $40.59 | 2022-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $35.87 | 2022-2023 | |
| Philips North America LLC | $24.84 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Astrazeneca Pharmaceuticals LP | $23.08 | 2021 | |
| Boston Scientific Corporation | $21.19 | 2024 | Wavewriter Alpha Prime 16 |
| Radius Health, INC. | $20.71 | 2020 | |
| Sunovion Pharmaceuticals INC. | $19.47 | 2021 | |
| Genentech USA, INC. | $18.91 | 2020 | |
| Axsome Therapeutics, INC. | $16.51 | 2025 | Symbravo |
| Idorsia Pharmaceuticals US INC | $14.66 | 2022 | |
| Allergan, INC. | $14.54 | 2020 | |
| Astellas Pharma US INC | $14.10 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Anoia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.